K. Lerch

90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years

P. Neumeister, A. Stroux, O. Lindén, 2022, Annals of Hematology.

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

C. Pott, A. Stroux, S. Lastoria, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary mycosis in surgery: Treatment with fluconazole

P. Kujath, K. Lerch, 1989, Infection.

Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses

P. Kujath, C. Boos, K. Lerch, 1993, Infection.

Fluconazole monitoring in Candida peritonitis based on histological control

P. Kujath, J. Dämmrich, K. Lerch, 1990, Mycoses.

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.

B. Dörken, K. Possinger, A. Stroux, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis

A. Stroux, R. Marks, A. Viardot, 2015, Annals of Hematology.

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

C. Pott, O. Lindén, G. Hess, 2010 .